Ixoberogene soroparvovec
Ixoberogene soroparvovec (Ixo-vec, also known as ADVM-022), is a gene therapy developed by Adverum Biotechnologies for wet age-related macular degeneration. It is delivered via the viral vector AAV.7m8.[1][2]
References[edit]
- ^ Gelfman, Claire M.; Grishanin, Ruslan; Bender, Kristina Oresic; Nguyen, Aivan; Greengard, Judith; Sharma, Pallavi; Nieves, Julio; Kiss, Szilárd; Gasmi, Mehdi (2021-04-01). "Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema". Journal of Ocular Pharmacology and Therapeutics. 37 (3): 181–190. doi:10.1089/jop.2021.0001. ISSN 1080-7683. PMC 8060718. PMID 33835848.
- ^ Grishanin, Ruslan; Vuillemenot, Brian; Sharma, Pallavi; Keravala, Annahita; Greengard, Judith; Gelfman, Claire; Blumenkrantz, Mark; Lawrence, Matthew; Hu, Wenzheng; Kiss, Szilárd; Gasmi, Mehdi (January 2019). "Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration". Molecular Therapy. 27 (1): 118–129. doi:10.1016/j.ymthe.2018.11.003. PMC 6319194. PMID 30528929.